The Value of Expression of M2-PK and VEGF in Patients with Advanced Gastric Cancer

Overview

Journal Cell Biochem Biophys

Specialties Biochemistry
Biophysics
Cell Biology

Date 2013 Apr 30

PMID 23625175

Citations 7

Authors

Lanning Yin

Xiang Wang

Changjiang Luo

Haipeng Liu

Ling Zhang

Hong Zhang

Youcheng Zhang

Affiliations

Soon will be listed here.

Abstract

Glycolytic pyruvate kinase isoenzyme type M2 (M2-PK) plays a key role in tumor metabolism and energy production. Vascular endothelial growth factor (VEGF) is critical in regulating angiogenesis which is an essential process required for tumor growth and metastasis. These two genes may function in accordance with tumor development. The purpose of this study was to investigate the relationship between the expression of M2-PK and VEGF, and their association with clinicopathological features in patients with advanced gastric cancer. Expression of M2-PK and VEGF were examined in 142 cases of paraffin-embedded tissue blocks from patients with advanced gastric cancer. M2-PK expression was found to strongly correlate with that of VEGF (r = 0.718). In addition, expression of M2-PK and VEGF correlates with tumor size (p = 0.0001, and p = 0.0017, respectively), depth of invasion (p = 0.0024, and p = 0.0261, respectively), and lymph node metastasis (p = 0.036, and p = 0.028, respectively). The high expression levels of M2-PK and VEGF may indicate poor prognosis in patients with advanced gastric cancer.

Citing Articles

Rev-erbα inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells.

Tao L, Yu H, Liang R, Jia R, Wang J, Jiang K Oncogenesis. 2019; 8(10):57.

PMID: 31591390 PMC: 6779746. DOI: 10.1038/s41389-019-0168-5.

PKM2, function and expression and regulation.

Zhang Z, Deng X, Liu Y, Liu Y, Sun L, Chen F Cell Biosci. 2019; 9:52.

PMID: 31391918 PMC: 6595688. DOI: 10.1186/s13578-019-0317-8.

PKM2 in carcinogenesis and oncotherapy.

He X, Du S, Lei T, Li X, Liu Y, Wang H Oncotarget. 2018; 8(66):110656-110670.

PMID: 29299177 PMC: 5746412. DOI: 10.18632/oncotarget.22529.

Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies.

Wu J, Hu L, Chen M, Cao W, Chen H, He T Onco Targets Ther. 2016; 9:4277-88.

PMID: 27478385 PMC: 4951066. DOI: 10.2147/OTT.S106508.

Glucose metabolism in gastric cancer: The cutting-edge.

Yuan L, Yamashita H, Seto Y World J Gastroenterol. 2016; 22(6):2046-59.

PMID: 26877609 PMC: 4726677. DOI: 10.3748/wjg.v22.i6.2046.

References

Pradeep C, Sunila E, Kuttan G . Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther. 2005; 4(4):315-21. DOI: 10.1177/1534735405282557. View

Catalano V, Labianca R, Beretta G, Gatta G, De Braud F, Van Cutsem E . Gastric cancer. Crit Rev Oncol Hematol. 2009; 71(2):127-64. DOI: 10.1016/j.critrevonc.2009.01.004. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Schneider J, Neu K, Grimm H, Velcovsky H, Weisse G, Eigenbrodt E . Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002; 22(1A):311-8. View

Akoh J, MacIntyre I . Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg. 1992; 79(4):293-9. DOI: 10.1002/bjs.1800790404. View

Oremek G, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel K . The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res. 1999; 19(4A):2599-601. View

Steinberg P, Klingelhoffer A, Schafer A, Wust G, Weisse G, Oesch F . Expression of pyruvate kinase M2 in preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch. 1999; 434(3):213-20. DOI: 10.1007/s004280050330. View

Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K . Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer. 2000; 83(8):986-91. PMC: 2363551. DOI: 10.1054/bjoc.2000.1427. View

Goonetilleke K, Mason J, Siriwardana P, King N, France M, Siriwardena A . Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas. 2007; 34(3):318-24. DOI: 10.1097/MPA.0b013e31802ee9c7. View

10.

Kleespies A, Bruns C, Jauch K . Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie. 2005; 28(5):281-8. DOI: 10.1159/000085198. View

11.

Takahashi Y, Kitadai Y, Bucana C, Cleary K, Ellis L . Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18):3964-8. View

12.

Hefler L, Zeillinger R, Grimm C, Sood A, Cheng W, Gadducci A . Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006; 103(2):512-7. DOI: 10.1016/j.ygyno.2006.03.058. View

13.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

14.

Iwasaki J, Nihira S . Anti-angiogenic therapy against gastrointestinal tract cancers. Jpn J Clin Oncol. 2009; 39(9):543-51. DOI: 10.1093/jjco/hyp062. View

15.

Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere J, Benamouzig R . Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006; 94(12):1823-32. PMC: 2361355. DOI: 10.1038/sj.bjc.6603176. View

16.

Schneider J, Neu K, Velcovsky H, Morr H, Eigenbrodt E . Tumor M2-pyruvate kinase in the follow-up of inoperable lung cancer patients: a pilot study. Cancer Lett. 2003; 193(1):91-8. DOI: 10.1016/s0304-3835(02)00720-6. View

17.

Linderholm B, Lindh B, Beckman L, Erlanson M, Edin K, Travelin B . Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer. 2004; 4(5):340-7. DOI: 10.3816/cbc.2003.n.039. View

18.

Schulze G . The tumor marker tumor M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res. 2001; 20(6D):4961-4. View

19.

Eigenbrodt E, Reinacher M, Scheefers H, Friis R . Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog. 1992; 3(1-2):91-115. View

20.

Zetter B . Angiogenesis and tumor metastasis. Annu Rev Med. 1998; 49:407-24. DOI: 10.1146/annurev.med.49.1.407. View